CP-690550, a janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway

Transplantation

Volumn 90, Issue 8, 2010, Pages 825-835

  Park, Hyung Bae ^a   Oh, Keunhee ^a   Garmaa, Nandin ^a   Seo, Myung Won ^a   Byoun, Ok Jin ^a   Lee, Hee Yoon ^b   Lee, Dong Sup ^a  

^a Seoul National University   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Anergy; CD4+ T; CP 690550; GVHD; IFN ; JAK; STAT5

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; GAMMA INTERFERON; JANUS KINASE; CYTOKINE; INTERLEUKIN 2; JANUS KINASE 3; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; STAT3 PROTEIN; STAT3 PROTEIN, MOUSE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS MIXED LYMPHOCYTE REACTION; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SYNTHESIS; HELPER CELL; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LETHALITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH17 CELL; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CELL DIFFERENTIATION; CYTOLOGY; DENDRITIC CELL; DRUG ANTAGONISM; DRUG EFFECT; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METABOLISM; MOUSE STRAIN; PHOSPHORYLATION;

ANIMALS; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; GRAFT VS HOST DISEASE; INTERFERON-GAMMA; INTERLEUKIN-2; JANUS KINASE 3; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; PHOSPHORYLATION; PYRIMIDINES; PYRROLES; STAT3 TRANSCRIPTION FACTOR;

EID: 78349287650     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f24e59     Document Type: Article

References (42)

1. Shlomchik WD. Graft versus host disease. Nat Rev Immunol 2007; 7: 340.
2. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25: 139.
3. Ball LM, Egeler RM; EBMT Paediatric Working Party. Acute GvHD: Pathogenesis and classification. Bone Marrow Transplant 2008; 41(suppl 2): S58.
4. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft versus-host-disease. Eur J Immunol 1993; 23: 333.
5. BacigalupoA, Van Lint MT, Occhini D,etal. Increased riskof leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423.
6. Blazar BR, Taylor PA, Fitzsimmons WE, et al. FK506 inhibits graft-versus host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. J Immunol 1994; 153: 1836.
7. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109: 3108.
8. Blazar BR, Taylor PA, Panoskaltsis-MortariA,et al. Rapamycin inhibits the generationof graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cyto-toxic cytokines. J Immunol 1998; 160: 5355.
9. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A. Blood 1996; 87: 4001.
10. Messina C, Faraci M, de Fazio V, et al. Prevention and treatment of acute GvHD. Bone Marrow Transplant 2008; 41(suppl 2): S65.
11. Russell SM, Johnston JA, Noguchi M, et al. Interaction of IL-2R /3 and y c chains with JAK1 and JAK3: Implications for XSCID and XCID. Science 1994; 266: 1042.
12. Thomis DC, Berg LJ. Peripheral expression of JAK3 is required to maintain T lymphocyte function. J Exp Med 1997; 185: 197.
13. O'Shea JJ, Pesu M, Borie DC, et al. A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nat Rev Drug Dis 2004; 3: 555.
14. Borie DC, O'Shea JJ, Changelian PS. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med 2004; 10:532.
15. Behbod F, Erwin-Cohen RA, Wang ME, et al. Concomitant inhibition of JAK3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol 2001; 166:3724.
16. Stepkowski SM, Erwin-Cohen RA, Behbod F, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002; 99: 680.
17. Cetkovic-Cvrlje M, Roers BA, Waurzyniak B, et al. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 2001; 98: 1607.
18. Uckun FM, Roers BA, Waurzyniak B, et al. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood 2002; 99: 4192.
19. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875.
20. Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004; 4: 51.
21. Borie DC, Changelian PS, Larson MJ, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 2005; 79: 791.
22. Paniagua R, Si MS, Flores MG, et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in non-human primate recipients of kidney allografts. Transplantation 2005; 80: 1283.
23. Ernst B, Lee DS, Chang JM, et al. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 1999; 11: 173.
24. Lee DS, Ahn C, Ernst B, et al. Thymic selection by a single MHC/ peptide ligand: Autoreactive T cells are low-affinity cells. Immunity 1999; 10: 83.
25. + T cell-mediated graft-versus-host disease: Effects of conditioning. Biol Blood Marrow Transplant 2000; 6: 604.
26. Cetkovic-Cvrlje M, Tibbles HE. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors. Curr Pharm Design 2004; 10: 1767.
27. Cetkovic-Cvrlje M, Roers BA, Schonhoff D, et al. Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor. Leuk Lymphoma 2002; 43: 1447.
28. Tibbles HE, Vassilev A, Wendorf H, et al. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J Biol Chem 2001; 276: 17815.
29. Oh K, Joo KM, Jung YS, et al. A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors. J Immunol Methods 2010; 354: 45.
30. Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors. Blood 2008; 111: 2155.
31. Kudlacz E, Conklyn M, Andresen C, et al. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 2008; 582: 154.
32. van Gurp EA, Schoordijk-Verschoor W, Klepper M, et al. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 2009; 87: 79.
33. Quaedackers ME, MolW, Korevaar SS, etal. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 2009; 88: 1002.
34. Sprent J, Schaefer M, Korngold R. Role of T cell subsets in lethal graft-versus host disease (GVHD) directed to class I versus class II H-2 differences. II. Protective effects of L3T4+ cells in anti-class II GVHD. J Immunol 1990; 144: 2946.
35. Shi M, Lin TH, Appell KC, et al. Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 2008; 28: 763.
36. Ellison CA, Fischer JM, HayGlass KT, et al. Murine graft-versus-host disease in an F1-hybrid model using IFN-y gene knockout donors. J Immunol 1998; 161: 631.
37. Murphy WJ, Welniak LA, Taub DD, et al. Differential effects of the absence of interferon-y and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 1998; 102: 1742.
38. Willenborg DO, Fordham S, Bernard CC, et al. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996; 157: 3223.
39. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177:566.
40. Subramaniam SV, Cooper RS, Adunyah SE. Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Bio-chem Biophys Res Commun 1999; 262: 14.
41. Yi T, Zhao D, Lin C, et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 2008; 112: 2101.
42. Yang YG, Dey BR, Sergio JJ, et al. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. JClinInvest 1998; 102:2126.